GYRE (Gyre Therapeutics, Inc. Common Stock) Stock Analysis - AI Report

Gyre Therapeutics, Inc. Common Stock (GYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, GYRE trades at $6.10 with a market cap of $624.86M and a P/E ratio of 100.58. GYRE moved -3.35% today. Year to date, GYRE is -23.74%; over the trailing twelve months it is -47.02%. Its 52-week range spans $6.01 to $19.00. Analyst consensus is buy with an average price target of $19.00. Rallies surfaces GYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on GYRE?

Rallies AI research for GYRE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

GYRE Key Metrics

Key financial metrics for GYRE
MetricValue
Price$6.10
Market Cap$624.86M
P/E Ratio100.58
EPS$0.06
Dividend Yield0.24%
52-Week High$19.00
52-Week Low$6.01
Volume100
Avg Volume0
Revenue (TTM)$116.59M
Net Income$9.88M
Gross Margin95.36%

Latest GYRE News

Recent GYRE Insider Trades

  • Luo Ying sold 10.14K (~$81.49K) on May 6, 2026.
  • Luo Ying sold 179 (~$1.43K) on May 5, 2026.
  • Ma Songjiang sold 558 (~$5.62K) on May 28, 2025.

GYRE Analyst Consensus

2 analysts cover GYRE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.00.

Common questions about GYRE

What is the AI research view on GYRE?
Rallies AI research for GYRE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for GYRE?
Rallies AI research for GYRE combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is GYRE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for GYRE. It does not provide personalized investment advice.
GYRE

GYRE